Recently, Shenzhen Cell Valley has achieved another milestone in the field of intellectual property—the "Anti-CD38 CAR Molecule Targeting CD38 Inhibition via shRNA and Its Drug" (Patent No.: CN116656743A), jointly developed by Shenzhen Cell Valley and the Shenzhen Beijing University of Chinese Medicine Research Institute, has been officially granted a national invention patent! This marks another groundbreaking achievement for Shenzhen Cell Valley in the core technology domain of cell immunotherapy.

This invention is exclusively owned by Shenzhen Cell Valley with full intellectual property rights. By innovatively applying cutting-edge shRNA gene editing technology, the company has successfully constructed anti-CD38 CAR-T cells targeting CD38 inhibition via shRNA. This technology effectively addresses the critical bottleneck of CAR-T cells in the "self-consumption and self-stimulation" cycle, significantly enhancing the expansion capability, persistence, and functional stability of anti-CD38 CAR-T cells, thereby pioneering a new technological pathway and application prospects for the treatment of major diseases such as hematologic malignancies.

The successful authorization of this patent represents another major scientific achievement for Shenzhen Cell Valley following its acquisition of three national invention patents in June 2025, further highlighting the company's core innovative capabilities and leading positioning in retroviral vectors, CAR-T cell technology, and gene editing.

Moving forward, Shenzhen Cell Valley will use such patents as a new starting point to accelerate the establishment of an independent intellectual property system in the cell and gene therapy field, with a focus on continuous advancements in areas such as new target discovery, molecular structure optimization, and innovative drug delivery systems. Simultaneously, the company will collaborate with industry-academia-research partners to promote the preclinical research and commercialization of this patented technology, bringing more hope and breakthroughs to cancer patients worldwide.

This achievement not only signifies another leap in Shenzhen Cell Valley's scientific innovation capabilities but also showcases China's growing global influence in the cell and gene therapy field!